Camel-IDS is a biotech company developing targeted radionuclide therapeutic solutions against cancer. Its product is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (Camelids), coupled with a therapeutic radioisotope.